Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.
Also called NCT02194595
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 105 participants
- Sponsor
- Registry
-
NCT02194595
-
- Other papers using this trial's data
- The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT02194595. Randomized; no masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2021-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)
- Acronym
- PREVAIL
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Basal insulin and exenatide
- Intervention (Drug)
- Basal insulin only
- Intervention (Drug)
- Basal insulin and bolus insulin
- Lead sponsor
- Mount Sinai Hospital, Canada
- Collaborator
- Canadian Institutes of Health Research (CIHR)
- Collaborator
- University of Toronto
Record details
- Record id
cardio:ct-nct02194595- Content hash
3c3aff4ba7e6b046df08104f46dbe6cbd99200a590977d180db75a5c933c8267